Please use this identifier to cite or link to this item:
Title: Association between single-nucleotide polymorphisms in DNA double-strand break repair genes and prostate cancer aggressiveness in the Spanish population.
Authors: Henríquez-Hernández, L A
Valenciano, A
Foro-Arnalot, P
Álvarez-Cubero, M J
Cozar, J M
Suárez-Novo, J F
Castells-Esteve, M
Fernández-Gonzalo, P
De-Paula-Carranza, B
Ferrer, M
Guedea, F
Sancho-Pardo, G
Craven-Bartle, J
Ortiz-Gordillo, M J
Cabrera-Roldán, P
Rodríguez-Melcón, J I
Herrera-Ramos, E
Rodríguez-Gallego, C
Lara, P C
metadata.dc.subject.mesh: Antigens, Nuclear
DNA Breaks, Double-Stranded
DNA Helicases
DNA Repair
DNA-Binding Proteins
Genetic Association Studies
Genetic Predisposition to Disease
Ku Autoantigen
Neoplasm Grading
Neoplasm Staging
Poly (ADP-Ribose) Polymerase-1
Poly(ADP-ribose) Polymerases
Polymorphism, Single Nucleotide
Prostatic Neoplasms
Risk Factors
Vault Ribonucleoprotein Particles
Issue Date: 12-Jan-2016
Abstract: Novel predictors of prognosis and treatment response for prostate cancer (PCa) are required to better individualize treatment. Single-nucleotide polymorphisms (SNPs) in four genes directly (XRCC5 (X-ray repair complementing defective repair in Chinese hamster cells 5) and XRCC6 (X-ray repair complementing defective repair in Chinese hamster cells 6)) or indirectly (PARP1 and major vault protein (MVP)) involved in non-homologous end joining were examined in 494 Spanish PCa patients. A total of 22 SNPs were genotyped in a Biotrove OpenArray NT Cycler. Clinical tumor stage, diagnostic PSA serum levels and Gleason score at diagnosis were obtained for all participants. Genotypic and allelic frequencies were determined using the web-based environment SNPator. (XRCC6) rs2267437 appeared as a risk factor for developing more aggressive PCa tumors. Those patients carrying the GG genotype were at higher risk of developing bigger tumors (odds ratio (OR)=2.04, 95% confidence interval (CI) 1.26-3.29, P=0.004), present higher diagnostic PSA levels (OR=2.12, 95% CI 1.19-3.78, P=0.011), higher Gleason score (OR=1.65, 95% CI 1.01-2.68, P=0.044) and D'Amico higher risk tumors (OR=2.38, 95% CI 1.24-4.58, P=0.009) than those patients carrying the CC/CG genotypes. Those patients carrying the (MVP) rs3815824 TT genotype were at higher risk of presenting higher diagnostic PSA levels (OR=4.74, 95% CI 1.40-16.07, P=0.013) than those patients carrying the CC genotype. When both SNPs were analyzed in combination, those patients carrying the risk genotypes were at higher risk of developing D'Amico higher risk tumors (OR=3.33, 95% CI 1.56-7.17, P=0.002). We believe that for the first time, genetic variants at XRCC6 and MVP genes are associated with risk of more aggressive disease, and would be taken into account when assessing the malignancy of PCa.
metadata.dc.identifier.doi: 10.1038/pcan.2015.63
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.